Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial

BJU International
Sender HerschornJason Gong

Abstract

To compare the efficacy and tolerability of fesoterodine 8 mg with tolterodine extended-release (ER) 4 mg and placebo in a randomized clinical trial of patients with an overactive bladder (OAB). In this 12-week double-blind, double-dummy, placebo-controlled, randomized clinical trial, eligible patients reported OAB symptoms for > or = 3 months and recorded > or = 8 voids and > or = 1 urgency urinary incontinence (UUI) episode per 24 h in 3-day bladder diaries at baseline. Patients were randomized in a 2:2:1 ratio to fesoterodine (4 mg for 1 week then 8 mg for 11 weeks); tolterodine ER 4 mg; or placebo (with sham dose escalation for tolterodine ER and placebo). Endpoints were changes from baseline to week 12 in UUI episodes (primary endpoint), total and nocturnal voids, urgency episodes, severe urgency episodes, and frequency-urgency sum per 24 h; mean voided volume per void (MVV); and the OAB questionnaire (OAB-q), Patient Perception of Bladder Condition (PPBC), and Urgency Perception Scale (UPS). Safety and tolerability were assessed and summarized over the 12-week study period. Fesoterodine (636 patients) significantly improved UUI episodes at week 12 (primary endpoint) compared with tolterodine ER (641 patients; P = 0.017) a...Continue Reading

References

Dec 22, 1978·Radiation and Environmental Biophysics·E Box
Mar 15, 2001·Urology·P Van KerrebroeckUNKNOWN Tolterodine Study Group
Sep 11, 2002·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·K CoyneP Abrams
Dec 25, 2003·Lancet Neurology·Karl-Erik Andersson
Feb 12, 2005·BJU International·Linda CardozoEboo Versi
Dec 13, 2005·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Andreas M PleilCon J Kelleher
Jul 4, 2006·The Journal of Urology·Karin S CoyneVikram Khullar
Oct 17, 2007·The Journal of Urology·Victor W NittiTamara Bavendam
Nov 3, 2007·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·Timothy P TurkstraPhilip M Jones
May 24, 2008·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Kim A Madewell, Phil Kuo
Jun 20, 2008·BJU International·Con J KelleherZoe Kopp
Jul 24, 2008·BJU International·Christopher R ChappleMarina Brodsky
Nov 13, 2008·International Journal of Clinical Pharmacology and Therapeutics·B MalhotraK Gandelman
Nov 27, 2008·Current Medical Research and Opinion·Sender HerschornUNKNOWN Disease Management Study Team
Aug 4, 2009·Urology·Roger R Dmochowski, Roger Dmochowski

❮ Previous
Next ❯

Citations

Mar 14, 2012·International Urogynecology Journal·Chiara Dell'UtriVik Khullar
Aug 8, 2013·Current Urology Reports·Ricardo NatalinMiriam Dambros
Mar 6, 2010·International Journal of Clinical Practice·P E V Van KerrebroeckZ Guan
Jun 21, 2011·Advances in Urology·Anastasios Athanasopoulos, Konstantinos Giannitsas
Jan 29, 2014·Drug Design, Development and Therapy·Vikky Morris, Adrian Wagg
Dec 4, 2012·International Journal of General Medicine·Jean-Jacques Wyndaele
Nov 8, 2013·International Urogynecology Journal·Antoni Sicras-MainarMarion Kvasz
Mar 8, 2014·Women's Health·Dudley Robinson, Linda Cardozowan
Jul 3, 2010·Digestive Diseases and Sciences·Patrick D MeekBora Gumustop
Dec 29, 2013·Expert Opinion on Pharmacotherapy·Angie RantellSushma Srikrishna
Apr 6, 2013·Expert Opinion on Pharmacotherapy·Ariana Smith, Alan Wein
Dec 15, 2015·Expert Opinion on Drug Delivery·Katie ScottPriya Padmanabhan
Apr 14, 2010·Expert Opinion on Emerging Drugs·Monika VijLinda Cardozo
Nov 12, 2013·Expert Opinion on Drug Metabolism & Toxicology·Stephen Mock, Roger R Dmochowski
Feb 9, 2011·Expert Opinion on Pharmacotherapy·Anastasios Athanasopoulos, Francisco Cruz
Jun 7, 2011·Expert Opinion on Drug Safety·Maria Vella, Linda Cardozo
Sep 12, 2015·Expert Opinion on Emerging Drugs·Roopali Karmarkar, Vik Khullar
Mar 25, 2011·Current Medical Research and Opinion·Jacques CorcosUNKNOWN Fesoterodine Assessment and Comparison Versus Tolterodine (FACT) Study Group
Mar 2, 2011·Current Medical Research and Opinion·Harriette ScarperoMartin Carlsson
Oct 15, 2013·Actas urologicas españolas·F Sánchez-BallesterD Arumi
Feb 5, 2013·Actas urologicas españolas·R García-BaqueroJ L Álvarez-Ossorio
Oct 20, 2012·The Journal of Urology·Victor W NittiSender Herschorn
Sep 19, 2012·European Urology·Malcolm G LucasUNKNOWN European Association of Urology
Nov 15, 2011·Maturitas·Boris van Doorn, J L H Ruud Bosch
Oct 20, 2010·The Urologic Clinics of North America·Anne P Cameron
Sep 28, 2010·BJU International·Howard B GoldmanTim Schneider
Sep 24, 2010·BJU International·Jean-Jacques WyndaeleMyung-Soo Choo
Jul 6, 2013·BJU International·Andrea Tubaro, Cosimo De Nunzio
Nov 23, 2012·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·A E BharuchaZ Guan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.